Faster onset of antidepressant effects of citalopram compared with sertraline in drug-naïve first-episode major depressive disorder in a chinese population: A 6-week double-blind, randomized comparative study

Journal of Clinical Psychopharmacology

Volumn 31, Issue 5, 2011, Pages 577-581

  Hsu, Ju Wei ^a,b   Su, Tung Ping ^a,b   Huang, Chen Ying ^a,b   Chen, Ying Sheue ^a,b   Chou, Yuan Hwa ^a,b,c  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b Department of Psychiatry ^*  (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Antidepressant; citalopram; clinical trials; major depressive disorder; sertraline

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; SERTRALINE;

ADULT; ARTICLE; ASTHENIA; CHINESE; CONSTIPATION; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HAND TREMOR; HEADACHE; HUMAN; INSOMNIA; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; SWEATING; TAIWAN; TREATMENT OUTCOME; XEROSTOMIA;

ADULT; CHINA; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80052440407     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31822c091a     Document Type: Article

References (38)

1. Roses AD. Pharmacogenetics and future drug development and delivery. Lancet. 2000;355:1358-1361. (Pubitemid 30199015)
2. Papakostas GI, Thase ME, Fava M, et al. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorderi A meta-analysis of studies of newer agents. Biol Psychiatry. 2007;62:1217-1227. (Pubitemid 350060895)
3. Gelenberg AJ, Chesen CL. How fast are antidepressants? J Clin Psychiatry. 2000;61:712-721.
4. Mancama D, Kerwin RW. Role of pharmacogenomics in individualising treatment with SSRIs. CNS Drugs. 2003;17:143-151. (Pubitemid 36286531)
5. Lesch KP, Gutknecht L. Pharmacogenetics of the serotonin transporter. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:1062-1073. (Pubitemid 41080133)
6. Lesch KP, Bengel D, Heils A, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996;274:1527-1531. (Pubitemid 26403928)
7. Heils A, Teufel A, Petri S, et al. Allelic variation of human serotonin transporter gene expression. J Neurochem. 1996;66:2621-2624. (Pubitemid 26159101)
8. Smits KM, Smits LJ, Schouten JS, et al. Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review. Mol Psychiatry. 2004;9:433-441. (Pubitemid 38903501)
9. Lee MS, Lee HY, Lee HJ, et al. Serotonin transporter promoter gene polymorphism and long-term outcome of antidepressant treatment. Psychiatr Genet. 2004;14:111-115.
10. Smeraldi E, Zanardi R, Benedetti F, et al. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry. 1998;3:508-511. (Pubitemid 28515526)
11. Zanardi R, Benedetti F, Di Bella D, et al. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol. 2000;20:105-107. (Pubitemid 30056365)
12. Ng CH, Easteal S, Tan S, et al. Serotonin transporter polymorphisms and clinical response to sertraline across ethnicities. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:953-957. (Pubitemid 43795359)
13. Kasper S, Olie JP. A meta-analysis of randomized controlled trials of tianeptine versus SSRI in the short-term treatment of depression. Eur Psychiatry. 2002;3:331-340. (Pubitemid 34839396)
14. Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996;31:444-469. (Pubitemid 26415952)
15. Kasper S, Spadone C, Verpillat P, et al. Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis. Int Clin Psychopharmacol. 2006;21:105-110. (Pubitemid 43740318)
16. Baumann P. Pharmacology and pharmacokinetics of citalopram and other SSRIs. Int Clin Psychopharmacol. 1996;1:5-11.
17. Klein MB, Cooper C, Brouillette M-J, et al. CTN-194 (PICCO): design of a trial of citalopram for the prevention of depression and its consequences in HIV-hepatitis C co-infected individuals initiating pegylated interferon/ribavirin therapy. Contemp Clin Trials. 2008;29:617-630.
18. Bauer M, Whybrow PC, Angst J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: acute and continuation treatment of major depressive disorder. World J Biol Psychiatry. 2002;3:5-43.
19. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389. (Pubitemid 9136500)
20. Chou Y-H, Wang S-J, Lin C-L, et al. Decreased brain serotonin transporter binding in the euthymic state of bipolar I but not bipolar II disorder: a SPECT study. Bipolar Disord. 2010;12:312-318.
21. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59 (suppl 20):22-33; quiz 34-57. (Pubitemid 29001829)
22. Rocca P, Calvarese P, Faggiano F, et al. Citalopram versus sertraline in late-life nonmajor clinically significant depression: a 1-year follow-up clinical trial. J Clin Psychiatry. 2005;66:360-369. (Pubitemid 40476760)
23. Stahl SM. Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline. Biol Psychiatry. 2000;48:894-901.
24. Ekselius L, von Knorring L, Eberhard G. A double-blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general practice. Int Clin Psychopharmacol. 1997;12:323-331. (Pubitemid 28133230)
25. Frazer A, Benmansour S. Delayed pharmacological effects of antidepressants. Mol Psychiatry. 2002;7:S23-S28. (Pubitemid 34280645)
26. Frazer A, Pandey G, Mendels J, et al. The effect of tri-iodothyronine in combination with impramine on [3H]-cyclic AMP production in slices of rat cerebral cortex. Neuropharmacology. 1974;13:1311-1340.
27. Mongeau R, Blier P, de Montigny C. The serotonergic and noradrenergic systems of the hippocampus: their interactions and the effects of antidepressant treatments. Brain Res Brain Res Rev. 1997;23:145-195. (Pubitemid 27189731)
28. Taylor MJ, Freemantle N, Geddes JR, et al. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch Gen Psychiatry. 2006;63:1217-1223. (Pubitemid 44708080)
29. Szegedi A, Jansen WT, van Willigenburg APP, et al. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry. 2009;70:344-353.
30. Sanchez C, Papp M. The selective sigma2 ligand Lu 28-179 has an antidepressant-like profile in the rat chronic mild stress model of depression. Behav Pharmacol. 2000;11:117-124. (Pubitemid 30315846)
31. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009;373:746-758.
32. Hansen RA, Gartlehner G, Lohr KN, et al. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med. 2005;143:415-426. (Pubitemid 41341413)
33. Yu BN, Chen GL, He N, et al. Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19. Drug Metab Dispos. 2003;31:1255-1259. (Pubitemid 37152977)
34. Desta Z, Zhao X, Shin JG, et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002;41:913-958. (Pubitemid 35168437)
35. Bialik RJ, Ravindran AV, Bakish D, et al. A comparison of placebo responders and nonresponders in subgroups of depressive disorder. J Psychiatry Neurosci. 1995;20:265-270.
36. Leon AC. Measuring onset of antidepressant action in clinical trials: an overview of definitions and methodology. J Clin Psychiatry. 2001;62(suppl 4):12-16; discussion 37-40. (Pubitemid 32183560)
37. Montgomery SA, Bech P, Blier P, et al. Selecting methodologies for the evaluation of differences in time to response between antidepressants. J Clin Psychiatry. 2002;63:694-699.
38. Matreja PS, Badyal DK, Khosla P, et al. Effectiveness and acceptability of sertraline and citalopram in major depressive disorder: pragmatic randomized open-label comparison. Hum Psychopharmacol. 2007;22:477-482. (Pubitemid 47611303)